Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance

被引：0
|
作者：
Hirotsugu Uemura
Yoshihiko Tomita
Norio Nonomura
Kenji Yoshizaki
Takafumi Nakao
Nobuo Shinohara
机构：
[1] Kindai University Faculty of Medicine,Department of Urology
[2] Niigata University Graduate School of Medical and Dental Sciences,Department of Urology, Department of Molecular Oncology
[3] Osaka University Graduate School of Medicine,Department of Urology
[4] Ono Pharmaceutical Co.,Safety Management Pharmacovigilance Division
[5] Ltd.,Department of Renal and Genitourinary Surgery
[6] Hokkaido University Graduate School of Medicine,undefined
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Effectiveness; Japan; Nivolumab; Post-marketing surveillance; Safety; Un-resectable or metastatic renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1061 / 1067
页数：6
相关论文
共 50 条
  • [1] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Nonomura, Norio
    Yoshizaki, Kenji
    Nakao, Takafumi
    Shinohara, Nobuo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (06) : 1061 - 1067
  • [2] Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
    Tahara, Makoto
    Kiyota, Naomi
    Nibu, Ken-ichi
    Akamatsu, Ayumi
    Hoshino, Tomohiro
    Hayashi, Ryuichi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (09) : 1619 - 1627
  • [3] Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
    Makoto Tahara
    Naomi Kiyota
    Ken-ichi Nibu
    Ayumi Akamatsu
    Tomohiro Hoshino
    Ryuichi Hayashi
    [J]. International Journal of Clinical Oncology, 2021, 26 : 1619 - 1627
  • [4] A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
    Yamazaki, N.
    Kiyohara, Y.
    Sato, M.
    Endo, S.
    Song, B.
    Tanaka, Y.
    Kambe, A.
    Sato, Y.
    Uhara, H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1601 - S1602
  • [5] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [6] The real-world use of istradefylline for Parkinsons disease: Post-marketing surveillance of safety and effectiveness in Japan
    Takahashi, Makio
    Itou, Satoru
    Horiguchi, Shuji
    Tsuji, Yukie
    [J]. NEUROLOGY, 2022, 98 (18)
  • [7] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Maruyama, Dai
    Omi, Ai
    Nomura, Fumi
    Touma, Tokiko
    Noguchi, Yukiko
    Takebe, Kyoko
    Izutsu, Koji
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (02) : 146 - 155
  • [8] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
    Dai Maruyama
    Ai Omi
    Fumi Nomura
    Tokiko Touma
    Yukiko Noguchi
    Kyoko Takebe
    Koji Izutsu
    [J]. International Journal of Hematology, 2024, 119 : 146 - 155
  • [9] Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan
    Takayama, Koichi
    Kojima, Ai
    Honda, Chikara
    Nakayama, Masahiro
    Kanemata, Satomi
    Endo, Toshimitsu
    Muro, Kei
    [J]. CANCER MEDICINE, 2024, 13 (09):
  • [10] Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan
    Kawasaki, Akira
    Hatake, Kiyohiko
    Matsumura, Itaru
    Izutsu, Koji
    Hoshino, Tomohiro
    Akamatsu, Ayumi
    Kakuuchi, Akito
    Tobinai, Kensei
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 667 - 676
12345